Mylan has acquired the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs, Inc.
According to the company’s press release, the transaction provides Mylan all assets and rights relating to the Cold-Eeze brand, including all U.S. businesses and U.S. and international trademarks. The Cold-Eeze brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the U.S.
Mylan CEO Heather Bresch sees this transaction as an important step in expanding the company’s consumer healthcare offerings. Cold-Eeze is now Mylan’s largest U.S. consumer healthcare brand and is part of a growing portfolio of over-the-counter products in the U.S., said Bresch.